Table 4.
Recommended conditions for common administration routes in mice (http://www.polyplus-transfection.com/in-vivo-reagents-therapeutics/dna-sirna-delivery-in-vivo-jetpei/)
| Animal | Site of injection | Starting conditions | Nucleic acid optimisation range | Injection volume Optimisation range (5% glucose) |
|---|---|---|---|---|
| Mouse | IV Tail vein/retro-orbital | 40 μg nucleic acid 6.4 μl reagent 200 μl of 5% glucose |
40–60 μg (1.6 – 2.4 mg/kg) | 200 – 400 μl |
| Intraperitoneal IP | 100 μg nucleic acid 16 μl reagent 1 ml 5%glucose |
100 – 200 μg (4 – 8 mg/kg) | 1 ml | |
| Subcutaneous (s.c.) | 5 μg nucleic acid 0.6 μl reagent 10 μl of 5% glucose |
3 – 5 μg | 5–15 μl |